<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="626">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828915</url>
  </required_header>
  <id_info>
    <org_study_id>TEDDI</org_study_id>
    <nct_id>NCT04828915</nct_id>
  </id_info>
  <brief_title>Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Max-Planck-Institute Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to use artificial intelligence in the form of machine learning&#xD;
      analysing vital signs as well as symptoms of patients suffering from Covid19 to identify&#xD;
      predictors of disease progression and severe course of disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Probability of Participants for Hospitalisation or Fatal Outcome</measure>
    <time_frame>Detection of severe acute respiratory syndrome- Corona Virus 2 (SARS-CoV2) to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probability of Participants for Intensive Care Unit Admission</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of Participants for Fatal Outcome</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction of persisting health impairment by using standardized questionnaires</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of symptoms, vital parameters and comorbidities predicting clinical course</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of size of training data set</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of viral load on the course of disease/ clinical outcome</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of different virus variants on the course of disease/ clinical outcome</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of SARS-CoV2 vaccination (yes/no) on the course of disease/ clinical outcome</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of parameters (symptoms, vital parameters, comorbidities) according to their potential of clinical course predictions</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of Participants for hospitalisation</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of different SARS-CoV2 vaccines on the course of disease/ clinical outcome</measure>
    <time_frame>Detection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Randomly selection of 80% of the study population. The machine learning algorithm is trained on this dataset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>Randomly selection of 20% of the study population. The machine learning algorithm which was trained on the basis of the training data cohort is validated on the validation cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Machine learning</intervention_name>
    <description>Machine learning on vital parameters, clinical symptoms and underlying diseases</description>
    <arm_group_label>Training cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Machine based evaluation</intervention_name>
    <description>Quantification of the prediction power and identification of the most relevant predictive parameters</description>
    <arm_group_label>Validation cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with detection of SARS-CoV2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Detection of SARS-CoV2 within the past 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to measure vital parameters and document symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bernhard Schoelkopf, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Max-Planck-Institute, Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Hetzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tuebingen, Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annika Buchholz, PhD</last_name>
    <phone>+49 151 51819576</phone>
    <email>annika.buchholz@tuebingen.mpg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Buchholz, Ph.D.</last_name>
      <phone>+4915151819576</phone>
      <email>annika.buchholz@tuebingen.mpg.de</email>
    </contact>
    <contact_backup>
      <last_name>Juergen Hetzel, M.D.</last_name>
      <phone>+491622919339</phone>
      <email>juergen.hetzel@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bijoy N Atique, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Hetzel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maik Haentschel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Machine learning</keyword>
  <keyword>Artificial intelligence</keyword>
  <keyword>Clinical course</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clinical Deterioration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

